An interesting therapeutic implication is that Treg activation may be achievable in a relatively tissue antigen-agnostic manner with attenuated IL-2 muteins, which could be used in a broad spectrum of auto-immune diseases. The gene discussed is IL2; the disease is immune system disorder.